Designing a multi-epitope vaccine against human cytomegalovirus: An immunoinformatic approach
Gastroenterology and Hepatology from Bed to Bench,
,
2 March 2026
,
Page 1-17 (e16)
https://doi.org/10.22037/ghfbb.v19i01.3161
Abstract
Background: Human Cytomegalovirus (HCMV) is ubiquitously found worldwide and poses significant health risks, particularly to individuals with compromised immune systems. Creating an effective vaccine is a crucial yet challenging component of combating its widespread prevalence. The primary objective was to use bioinformatics tools to design a multi-epitope vaccine targeting three antigenic HCMV proteins, aiming to prompt an immune response and offer protective efficacy.
Methods: Using immunoinformatic techniques, B-cell and T-cell epitopes from these proteins were predicted, selected, and assembled into a comprehensive multi-epitope vaccine construct. The proposed vaccine's immunogenic properties, structural stability, and safety profile were assessed through a series of computational analyses. Additionally, molecular docking with the human toll-like receptor 2 (TLR-2) was performed to evaluate the vaccine's binding affinity and potential for immune system activation.
Results: The analysis revealed that the engineered multi-epitope vaccine exhibited high antigenicity with a low risk of allergenicity, notable stability, and optimal solubility. Binding to human TLR2 was characterized by high affinity and specificity. Simulations of the immune response postulated that the introduced vaccine would generate a robust and enduring immune reaction, eliciting both antibody production and cytokine release, and engaging both humoral and cell-mediated immunity.
Conclusion: Results from the immunoinformatic investigation endorse the multi-epitope HCMV vaccine as a promising candidate, demonstrating potential efficacy that merits further experimental validation and exploration in clinical trials. The design supports optimistic projections for future HCMV vaccine development.
- Cytomegalovirus
- HCMV
- multi-epitope vaccine
- immunoinformatic
- HCMV vaccine
How to Cite
References
Rawlinson WD, Boppana SB, Fowler KB, Kimberlin DW, Lazzarotto T, Alain S, et al. Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy. 2017;17(6):e177-e88.
Kotton CN, Kumar D, Caliendo AM, Åsberg A, Chou S, Snydman DR, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. 2010;89(7):779-95.
Zuhair M, Smit GSA, Wallis G, Jabbar F, Smith C, Devleesschauwer B, et al. Estimation of the worldwide seroprevalence of cytomegalovirus: a systematic review and meta‐analysis. 2019;29(3):e2034.
Watkins RR, Lemonovich TL, Razonable RRJEroci. Immune response to CMV in solid organ transplant recipients: current concepts and future directions. 2012;8(4):383-93.
Limaye AP, Babu TM, Boeckh MJCMR. Progress and challenges in the prevention, diagnosis, and management of cytomegalovirus infection in transplantation. 2020;34(1):10.1128/cmr. 00043-19.
Kenneson A, Cannon MJJRimv. Review and meta‐analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. 2007;17(4):253-76.
Manicklal S, Emery VC, Lazzarotto T, Boppana SB, Gupta RKJCmr. The “silent” global burden of congenital cytomegalovirus. 2013;26(1):86-102.
Lidehäll AK, Engman ML, Sund F, Malm G, Lewensohn‐Fuchs I, Ewald U, et al. Cytomegalovirus‐Specific CD 4 and CD 8 T Cell Responses in Infants and Children. 2013;77(2):135-43.
Britt WJMm, immunology. Controversies in the natural history of congenital human cytomegalovirus infection: the paradox of infection and disease in offspring of women with immunity prior to pregnancy. 2015;204:263-71.
Gandhi MK, Khanna RJTLid. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. 2004;4(12):725-38.
Lawrence RS, Durch JS, Stratton KR. Vaccines for the 21st century: a tool for decisionmaking. 2001.
Weekes MP, Tomasec P, Huttlin EL, Fielding CA, Nusinow D, Stanton RJ, et al. Quantitative temporal viromics: an approach to investigate host-pathogen interaction. 2014;157(6):1460-72.
Ye X, Gui X, Freed DC, Ku Z, Li L, Chen Y, et al. Identification of adipocyte plasma membrane-associated protein as a novel modulator of human cytomegalovirus infection. 2019;15(7):e1007914.
Britt WJ, Vugler L, Butfiloski E, Stephens EJJov. Cell surface expression of human cytomegalovirus (HCMV) gp55-116 (gB): use of HCMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response. 1990;64(3):1079-85.
Nelson CS, Baraniak I, Lilleri D, Reeves MB, Griffiths PD, Permar SRJTJoID. Immune correlates of protection against human cytomegalovirus acquisition, replication, and disease. 2020;221(Supplement_1):S45-S59.
Plotkin SA, Wang D, Oualim A, Diamond DJ, Kotton CN, Mossman S, et al. The status of vaccine development against the human cytomegalovirus. 2020;221(Supplement_1):S113-S22.
Joon S, Singla RK, Shen B. Vaccines and Immunoinformatics for Vaccine Design. Translational Informatics: Prevention and Treatment of Viral Infections: Springer; 2022. p. 95-110.
UniProt: the universal protein knowledgebase %J Nucleic acids research. 2017;45(D1):D158-D69.
Doytchinova IA, Flower DRJBb. VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. 2007;8(1):1-7.
Nguyen MN, Krutz NL, Limviphuvadh V, Lopata AL, Gerberick GF, Maurer-Stroh SJNAR. AllerCatPro 2.0: a web server for predicting protein allergenicity potential. 2022;50(W1):W36-W43.
Wei L, Ye X, Sakurai T, Mu Z, Wei LJB. ToxIBTL: prediction of peptide toxicity based on information bottleneck and transfer learning. 2022;38(6):1514-24.
Sanchez-Trincado JL, Gomez-Perosanz M, Reche PAJJoir. Fundamentals and methods for T-and B-cell epitope prediction. 2017;2017.
Castelli FA, Buhot Cc, Sanson A, Zarour H, Pouvelle-Moratille S, Nonn Cl, et al. HLA-DP4, the most frequent HLA II molecule, defines a new supertype of peptide-binding specificity. 2002;169(12):6928-34.
Sette A, Newman M, Livingston B, McKinney D, Sidney J, Ishioka G, et al. Optimizing vaccine design for cellular processing, MHC binding and TCR recognition. 2002;59(6):443-51.
Rapin N, Lund O, Bernaschi M, Castiglione FJPo. Computational immunology meets bioinformatics: the use of prediction tools for molecular binding in the simulation of the immune system. 2010;5(4):e9862.
Zhang L, Skolnick JJPs. What should the Z‐score of native protein structures be? 1998;7(5):1201-7.
Oliveira-Nascimento L, Massari P, Wetzler LMJFii. The role of TLR2 in infection and immunity. 2012;3:79.
Hughes BL, Clifton RG, Rouse DJ, Saade GR, Dinsmoor MJ, Reddy UM, et al. A trial of hyperimmune globulin to prevent congenital cytomegalovirus infection. 2021;385(5):436-44.
Vanarsdall AL, Chin AL, Liu J, Jardetzky TS, Mudd JO, Orloff SL, et al. HCMV trimer-and pentamer-specific antibodies synergize for virus neutralization but do not correlate with congenital transmission. 2019;116(9):3728-33.
Schleiss MR, Bourne N, Stroup G, Bravo FJ, Jensen NJ, Bernstein DIJTJoid. Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine. 2004;189(8):1374-81.
Pass RF, Duliegè A-M, Boppana S, Sekulovich R, Percell S, Britt W, et al. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant. 1999;180(4):970-5.
Nelson CS, Cruz DV, Tran D, Bialas KM, Stamper L, Wu H, et al. Preexisting antibodies can protect against congenital cytomegalovirus infection in monkeys. 2017;2(13).
Wang D, Shenk TJPotNAoS. Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. 2005;102(50):18153-8.
John S, Yuzhakov O, Woods A, Deterling J, Hassett K, Shaw CA, et al. Multi-antigenic human cytomegalovirus mRNA vaccines that elicit potent humoral and cell-mediated immunity. 2018;36(12):1689-99.
Martinez-Martin N, Marcandalli J, Huang CS, Arthur CP, Perotti M, Foglierini M, et al. An unbiased screen for human cytomegalovirus identifies neuropilin-2 as a central viral receptor. 2018;174(5):1158-71. e19.
Kabanova A, Marcandalli J, Zhou T, Bianchi S, Baxa U, Tsybovsky Y, et al. Platelet-derived growth factor-α receptor is the cellular receptor for human cytomegalovirus gHgLgO trimer. 2016;1(8):1-8.
Plotkin SA, Boppana SBJV. Vaccination against the human cytomegalovirus. 2019;37(50):7437-42.
Navarro D, Paz P, Tugizov S, Topp K, La Vail J, Pereira LJV. Glycoprotein B of human cytomegalovirus promotes virion penetration into cells, transmission of infection from cell to cell, and fusion of infected cells. 1993;197(1):143-58.
Jalal K, Khan K, Uddin RJIR. Immunoinformatic-guided designing of multi-epitope vaccine construct against Brucella suis 1300. 2023;71(2):247-66.
Chauhan V, Singh MP. Immuno-informatics approach to design a multi-epitope vaccine to combat cytomegalovirus infection. European Journal of Pharmaceutical Sciences. 2020 Apr 30;147:105279.
Bakkari MA. Targeted protein-specific multi-epitope-based vaccine designing against human cytomegalovirus by using immunoinformatics approaches. Vaccines. 2023 Jan 17;11(2):203.
Quinzo MJ, Lafuente EM, Zuluaga P, Flower DR, Reche PA. Computational assembly of a human Cytomegalovirus vaccine upon experimental epitope legacy. BMC bioinformatics. 2019 Dec;20:1-1.
Barry PA, Iyer SS, Gibson L. Re-Evaluating Human Cytomegalovirus Vaccine Design: Prediction of T Cell Epitopes. Vaccines. 2023 Oct 24;11(11):1629.
Suleman M, Rashid F, Ali S, Sher H, Luo S, Xie L, et al. Immunoinformatic-based design of immune-boosting multiepitope subunit vaccines against monkeypox virus and validation through molecular dynamics and immune simulation. 2022;13:1042997.
Fadilah F, Paramita RI, Erlina L, Istiadi KA, Wuyung PE, Tedjo A, editors. Linker Optimization in Breast Cancer Multiepitope Peptide Vaccine Design Based on Molecular Study. 4th International Conference on Life Sciences and Biotechnology (ICOLIB 2021); 2022: Atlantis Press.
Rahman N, Ali F, Basharat Z, Shehroz M, Khan MK, Jeandet P, et al. Vaccine design from the ensemble of surface glycoprotein epitopes of SARS-CoV-2: an immunoinformatics approach. 2020;8(3):423.
Sanami S, Zandi M, Pourhossein B, Mobini G-R, Safaei M, Abed A, et al. Design of a multi-epitope vaccine against SARS-CoV-2 using immunoinformatics approach. 2020;164:871-83.
Aghdaei HA, Ghavami SB, Farmani M, Sherkat G, Shahrokh S, Zali MRJGR. Overexpression of toll-like receptors and co-stimulatory molecules on immature dendritic cells of Crohn's disease. 2022;27:101579.
Zheng M, Karki R, Williams EP, Yang D, Fitzpatrick E, Vogel P, et al. TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines. 2021;22(7):829-38.
Forrest C, Chase TJ, Cuff AO, Maroulis D, Motallebzadeh R, Gander A, et al. Control of human cytomegalovirus replication by liver resident natural killer cells. 2023;14(1):1409.
Baasch S, Giansanti P, Kolter J, Riedl A, Forde AJ, Runge S, et al. Cytomegalovirus subverts macrophage identity. 2021;184(14):3774-93. e25.
Mahmoodi S, Amirzakaria JZ, Ghasemian AJPo. In silico design and validation of a novel multi-epitope vaccine candidate against structural proteins of Chikungunya virus using comprehensive immunoinformatics analyses. 2023;18(5):e0285177.
Safavi A, Kefayat A, Mahdevar E, Abiri A, Ghahremani FJV. Exploring the out of sight antigens of SARS-CoV-2 to design a candidate multi-epitope vaccine by utilizing immunoinformatics approaches. 2020;38(48):7612-28.
- Abstract Viewed: 126 times
- PDF Downloaded: 73 times
- Supplementary Downloaded: 52 times